NPSP795
CAL-C13-001
Phase 2 small_molecule completed
Quick answer
NPSP795 for Autosomal Dominant Hypocalcemia (ADH) is a Phase 2 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).
Program details
- Company
- TAKEDA PHARMACEUTICAL CO LTD
- Indication
- Autosomal Dominant Hypocalcemia (ADH)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed